Breast Care最新文献

{"title":"Prognostic Impact of Immunophenotypic Variation in Subcapsular Sinus Endothelium of Sentinel Lymph Nodes in Invasive Breast Carcinoma.","authors":"Jonas Derben, Markus Oeruem, Carolin Blasberg, Akira Hattesohl, Paul Jank, Matthias Kalder, Carsten Denkert, Christina C Westhoff","doi":"10.1159/000543600","DOIUrl":"10.1159/000543600","url":null,"abstract":"<p><strong>Introduction: </strong>Several studies demonstrated the de novo formation of lymphatic vessels in tumor-draining lymph nodes (LNs), partly preceding lymphatic metastases. This \"lymphovascular niche\" supposedly facilitates survival of metastatic tumor cells. This study aims at evaluating the previously observed immunophenotypic variations of subcapsular endothelial cells (SECs) in a larger cohort by software-assisted image analysis.</p><p><strong>Methods: </strong>Suitable cases with sentinel-LN (SLN) of invasive breast cancer were identified in the Institute of Pathology, corresponding data were extracted. LN of 231 patients were stained for HE, D2-40, CD31, and Prox1. QuPath software was used for assessing the immunohistochemical stained area of endothelial cells of the subcapsular sinus. The Cutoff Finder web application was used for identification of the best cutoff for continuous parameters according to overall survival (OS). Collected data were statistically evaluated for available data.</p><p><strong>Results: </strong>A larger area of CD31-positive SEC was significantly associated with worse OS (<i>p</i> = 0.001), as was a higher proportion of D2-40-stained subcapsular sinus (<i>p</i> = 0.045). Larger area of D2-40-/CD31-/Prox1-positive SEC and higher proportion of D2-40 stained subcapsular sinus were independent marker for worse OS in multivariate analysis in the whole cohort, for D2-40- and CD31-positive SECs as well as higher proportion of D2-40-stained sinus including nodal-negative status, respectively.</p><p><strong>Conclusion: </strong>QuPath-assisted evaluation of immunophenotypic variation in subcapsular sinus endothelium in SLN essentially confirmed and extended our previous findings. Larger positive area of D2-40- and CD31-positive SECs emerged as a strong independent negative prognostic factor, even before evident nodal metastasis. The potential function of alterations in D2-40-/CD31-expression in SECs has yet to be elucidated.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 2","pages":"75-87"},"PeriodicalIF":2.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large-Scale Population Screening for <i>BRCA1</i> and <i>BRCA2</i> Ashkenazi Founder Mutations: Perspectives of Professionals Providing Oncogenetic Consultations.","authors":"Yael Furman, Yoel Gofin, Shira Litz Philipsborn, Shulamit Hartmajer, Rivka Sukenik-Halevy","doi":"10.1159/000543678","DOIUrl":"10.1159/000543678","url":null,"abstract":"<p><strong>Introduction: </strong>In March 2020, a nationwide population carrier screening for <i>BRCA1/2</i> pathogenic variants among Ashkenazi Jewish women was initiated in Israel. We aimed to assess views regarding the program among professionals who provide oncogenetic counseling for detected carriers.</p><p><strong>Methods: </strong>An online survey was distributed to clinical geneticists and genetic counselors.</p><p><strong>Results: </strong>The participants' impression was that most carriers did not comprehend the implications of a positive result when deciding to take the test. Some carriers, in retrospect, regretted taking it. Some had a known mutation carrier in the family, and some had a family history that justified a broader test (and so should not have been tested through the screening program). Eight survey participants (29%) reported they were initially against the screening program, but half of them are currently in favor of it. Most participants are unsatisfied with the way the screening is conducted and suggested various improvements. Emotional distress of carriers, as assessed by participants, was higher for those detected by the screening program, compared to those tested after oncogenetic counseling. No association was found between the age, profession, and prior experience of participants and their responses.</p><p><strong>Conclusions: </strong>While the general attitude toward the screening program is positive, most professionals feel the need to improve the current screening program by defining exclusion criteria, providing comprehensive pretest information and adding other BRCA1/2 founder mutations, as well as expanding the screening to include ethnicities other than Ashkenazi Jews.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 2","pages":"111-117"},"PeriodicalIF":2.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Risk Factors and Development and Validation of a Nomogram for Predicting Overall Survival in Breast-Invasive Lobular Carcinoma.","authors":"Mingjie Yuan, Ying Yin, Zhaoxin Chu, Jianming Yan","doi":"10.1159/000543865","DOIUrl":"10.1159/000543865","url":null,"abstract":"<p><strong>Objective: </strong>Invasive lobular carcinoma (ILC) of the breast is a common pathological subtype of breast cancer, ranks second in terms of incidence rate following invasive ductal carcinoma. The aims of this study were to construct a nomogram for predicting overall survival (OS) in patients with ILC and to identify risk factors that affect their survival prognosis.</p><p><strong>Methods: </strong>The patients diagnosed with ILC between 2010 and 2015 were extracted from Surveillance, Epidemiology, and End Results (SEER) database. They were randomly split into a training set with 18,365 samples for model training and parameter tuning and a validation set with 7,872 samples for independent accuracy verification. The independent risk factors were screened by lasso regression and multivariable Cox regression. A nomogram was constructed for the 3-year, 5-year, and 10-year OS rates based on these independent risk factors. Model efficiency was assessed through Harrell's concordance index (C-index), calibration curves, receiver operating characteristic curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>A total of 26,237 patients diagnosed with ILC were included. The following factors were identified as independent risk factors associated with OS: age, marital status, grade, estrogen receptor, progesterone receptor, surgery, radiation therapy, tumor size (T), lymph node (N), and metastasis (M) stages. The C-index was 0.795 in the training set, while in the validation set it was 0.791. The corresponding areas under the curve for 3-year, 5-year, and 10-year OS were 0.837, 0.828, and 0.791 in the training set and 0.832, 0.826, and 0.781 in the validation set, respectively. The calibration curve of the nomogram showed good consistency, and the DCA curves also suggested that it can provide valuable guidance for clinical decision-making.</p><p><strong>Conclusions: </strong>The established nomogram predicting 3-year, 5-year, and 10-year OS for patients with ILC showed a good performance and it can help clinicians make more favorable clinical decisions.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 2","pages":"118-131"},"PeriodicalIF":2.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Lifestyle and Genetic Risk Factors in Urban Women in China Who Had Malignant or Suspected Malignant Breast Nodules Identified via Breast Cancer Screening.","authors":"Jun-Luan Mo, Lin Lei, Xi Li, Hong-Hao Zhou, Li-Jun Zhang, Wen-Xu Hong, Ji-Ye Yin","doi":"10.1159/000545279","DOIUrl":"10.1159/000545279","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer seriously endangers women's health. It is very important to analyze the lifestyle and genetic risk factors for people with malignant or suspected malignant nodules in breast cancer screening for the prevention of breast cancer.</p><p><strong>Methods: </strong>A total of 3,142 urban female residents in southern China completed a clinical screening for breast cancer. The participants completed questionnaires on living environmental factors and underwent clinical imaging examinations and genetic testing of 73 SNP loci. According to the BI-RADS classification results, the population was divided into positive and negative groups. Key factors were identified through intergroup differences and association analysis. Lifestyle models, SNP models, and lifestyle + PRS models were constructed. ROC curves and nomograms were used to evaluate the classification effect of the model.</p><p><strong>Results: </strong>There were 10 lifestyle factors that were significantly different between the groups, 4 of which were significantly associated with positive breast imaging results (<i>p</i> < 0.05), including age (OR = 0.972, 95% CI: 0.957-0.988), duration of breastfeeding (0.982, 0.970-0.994), history of benign breast disease (1.838, 1.299-2.599), and high-fat diet (1.507, 1.166-1.947). There were 5 significant SNPs, including <i>BRCA2</i>-rs1799955, <i>TLR1</i>-rs4833095, <i>ZNF365</i>-rs10822013, <i>SLC4A7</i>-rs4973768, and <i>BRCA2</i>-rs144848. The AUC values for the lifestyle, SNP, and lifestyle + PRS models were 0.625, 0.598, and 0.633, respectively. The C index of the lifestyle + PRS model was 0.633.</p><p><strong>Conclusion: </strong>Advocating breastfeeding, reducing the intake of high-fat diets, and protecting breast health may help lower the risk of positive results in breast screenings. The combination of lifestyle factors and genetic factors can enhance the predictive power of the model.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-13"},"PeriodicalIF":2.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Banana Supplementation for Breast Cancer Surgery Patients: A Two-Center Experience.","authors":"Yang Jiang, Xin Ma, Lei Niu, Yaoyao Jiang","doi":"10.1159/000545174","DOIUrl":"10.1159/000545174","url":null,"abstract":"<p><strong>Introduction: </strong>Patients frequently encounter both physical and mental challenges after undergoing surgery for breast cancer, leading to a negative impact on their general well-being. Our objective was to investigate the beneficial effects of dietary supplementation with bananas on patients after breast cancer surgery.</p><p><strong>Methods: </strong>Among breast cancer patients who had undergone breast surgery, the banana group (<i>n</i> = 77) consumed an additional banana daily alongside their regular diet, while the non-banana group (<i>n</i> = 77) did not. Negative emotions, sleep quality, sexual health, complication rates, length of hospital stay, and quality of life were assessed.</p><p><strong>Results: </strong>Compared to the non-banana group, patients in the banana group exhibited lower levels of depression and anxiety, better sleep quality, more satisfactory sexual quality of life, and a higher overall quality of life postoperatively. Nonetheless, the complication rates and length of hospital stay did not show any notable variances between the 2 groups.</p><p><strong>Conclusion: </strong>This study highlights the novel finding that simple dietary supplementation with bananas significantly enhances mental well-being and overall quality of life in breast cancer patients following surgery, despite no notable impact on physical recovery metrics.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?","authors":"Stefan Lukac, Visnja Fink, Thomas W P Friedl, Franziska Mergel, Kerstin Pfister, Henning Schäffler, Davut Dayan, Sabine Heublein, Brigitte Rack, Wolfgang Janni, Elena Leinert","doi":"10.1159/000544906","DOIUrl":"10.1159/000544906","url":null,"abstract":"<p><strong>Objectives: </strong>Triple-negative breast cancer (TNBC) requires chemotherapy-based systemic treatment which is usually anthracycline-based (AB). The cardiotoxicity of AB regimens is especially relevant in the elderly population. Therefore, we retrospectively compared survival and toxicity between elderly patients with early TNBC receiving AB or anthracycline-free (AF) adjuvant chemotherapy to evaluate whether elderly patients with TNBC could be spared anthracycline-related toxicity without compromising survival.</p><p><strong>Methods: </strong>The study population comprised 221 women with TNBC older than 65 years from the SUCCESS A and SUCCESS C studies, who underwent primary surgery and received either AB (3x fluorouracil-epirubicin-cyclophosphamide followed by 3x docetaxel) or AF (6x docetaxel-cyclophosphamide) adjuvant chemotherapy according to a standardized protocol. The two groups were compared regarding clinicopathological parameters (pT, pN, grading, histological subtype, type of surgery, adjuvant radiotherapy) and side effects using chi-square tests, and regarding survival (overall survival, invasive disease-free survival, breast-cancer specific survival, distant disease-free survival) using log-rank tests and Cox regressions.</p><p><strong>Results: </strong>There was no significant difference between the two groups regarding any of the clinicopathological parameters, and no significant difference was observed in survival parameters. However, elderly patients with the AB regime had significantly more often grade 3 or 4 adverse events (75.2% vs. 50.6%, <i>p</i> < 0.001) during adjuvant chemotherapy than patients with the AF regimen.</p><p><strong>Conclusion: </strong>In our retrospective analysis of SUCCESS A and C trial, the use of AF chemotherapy in elderly patients with TNBC was associated with similar survival rates but less toxicity compared to AB chemotherapy. Further randomized controlled trials with AF regimen focusing on elderly patients with TNBC are necessary to confirm our results.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Preferences for HR+/HER2- Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment.","authors":"Victoria Harmer, Cathy Ammendolea, Mandy Ryan, Frances Boyle, Gustavo Werutsky, Dina El Mouzain, Deborah A Marshall, Caitlin Thomas, Sebastian Heidenreich, Hui Lu, Nicolas Krucien, Juan Mora Payan, Dawn Aubel, Andriy Danyliv, Purnima Pathak, Nadia Harbeck","doi":"10.1159/000543320","DOIUrl":"10.1159/000543320","url":null,"abstract":"<p><strong>Introduction: </strong>More adjuvant treatment options are becoming available for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) based on results of clinical trials. This study quantified the importance of different attributes of EBC adjuvant therapies to patients and the benefit-risk tradeoffs patients were willing to make.</p><p><strong>Methods: </strong>Women with HR+/HER2- EBC completed an online discrete choice experiment (DCE) survey; the design was informed by clinical data, qualitative interviews (<i>n</i> = 40), and pre-testing interviews (<i>n</i> = 40). Participants (pts) made 10 choices between pairs of hypothetical treatments described by varying levels of 6 attributes. DCE data were analyzed using a correlated mixed logit model. Relative attribute importance scores captured the impact of each attribute across clinically relevant ranges. Benefit-risk tradeoffs were captured as the minimum improvements in 5-year invasive disease-free survival (iDFS) that pts would require to tolerate increases in therapy-associated adverse event (AE) risks.</p><p><strong>Results: </strong>A total of 866 patients from the USA, France, Spain, Canada, the UK, Germany, South Korea, and Australia completed the DCE (mean age: 57.7 years; 76% postmenopausal; 29% stage I disease, 55% stage II, 16% stage III). Improved 5-year iDFS (75.4-82.7% range; associated with combination regimens [CRs] vs. endocrine therapy [ET] alone) contributed the most to treatment preferences (clinically relevant relative attribute importance: 38.4%), followed by reduced risks of venous thromboembolic events (VTEs) (20.4%), neutropenia (20.3%), and diarrhea (15.0%). Treatment type + duration (3.7%) and fatigue (2.3%) were less important. Pts required the largest improvement in 5-year iDFS (3.9%) to tolerate increased risks of VTE (0.7%-2.5%) or neutropenia (5.6%-46%); willingness to accept tradeoffs depended on the AE. Preference heterogeneity was observed across subgroups, but 5-year iDFS improvement was consistently the most impactful on treatment choice in all subgroups.</p><p><strong>Conclusion: </strong>A multicountry sample of patients most valued adjuvant therapies with higher 5-year iDFS and may therefore prefer CRs over ET alone. The value of CRs depends on their specific safety profiles, and shared decision-making should consider this to select treatment options that align with individual preferences.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"16-26"},"PeriodicalIF":2.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Discussion: ESMO 2024.","authors":"Christoph Thomssen, Maggie Banys-Paluchowski, François-Clément Bidard, Nancy U Lin","doi":"10.1159/000543115","DOIUrl":"10.1159/000543115","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"40-44"},"PeriodicalIF":2.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Importance of Panimmune-Inflammation Value and PILE Scores in Non-Metastatic Luminal A Breast Cancer.","authors":"Mukaddes Yılmaz, Eda Erdiş, Mahmut Uçar, Birsen Yücel","doi":"10.1159/000543304","DOIUrl":"10.1159/000543304","url":null,"abstract":"<p><strong>Introduction: </strong>The present study evaluated the prognostic significance of panimmune-inflammation value (PIV) and PILE (a composite score of PIV, lactate dehydrogenase [LDH], and Eastern Cooperative Oncology Group Performance Status [ECOG PS]) in patients with non-metastatic luminal A breast cancer.</p><p><strong>Methods: </strong>Non-metastatic stage (I-III) luminal A breast cancer patients who were admitted to Cumhuriyet University Oncology Center were retrospectively examined. The PIV score was calculated using the neutrophil, platelet, monocyte, and lymphocyte counts at the time of diagnosis. The PIV, LDH, and ECOG PS parameters were used for the PILE score.</p><p><strong>Results: </strong>A total of 293 patients were included. The median PIV was 254.89; 239 (82%) patients had low PILE score; and 54 (18%) patients had high PILE score. Patients with low PIV and low PILE scores had significantly better OS and disease-free survival (DFS) (PIV; <i>p</i> = 0.033 for OS and <i>p</i> = 0.024 for DFS and PILE; <i>p</i> = 0.001 for OS and <i>p</i> = 0.005 for DFS). The PIV and PILE scores were found to be significant prognostic factors associated with OS and DFS. The PIV score was found to be an independent prognostic factor for OS and DFS (OS: score 0 vs. 1; HR: 1.89, 95% CI: 1.06-3.35; <i>p</i> = 0.029; and DFS: score 0 vs. 1; HR: 1.75, 95% CI: 1.01-3.01; <i>p</i> = 0.044). The PILE score was not an independent prognostic factor associated with OS or DFS.</p><p><strong>Conclusion: </strong>Survival was better in those with lower PIV and PILE scores. The PIV score was an independent prognostic factor for survival in these patients.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"27-39"},"PeriodicalIF":2.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors for Upgrade to Breast Cancer in Patients with B3 Lesions Diagnosed by Core Biopsy: A Retrospective Cohort Study.","authors":"Burak Dinçer, Ceylan Yanar, Ramazan Uçak, Esma Çerekçi, Cemal Kaya","doi":"10.1159/000542551","DOIUrl":"10.1159/000542551","url":null,"abstract":"<p><strong>Background: </strong>The optimal approach to B3 lesions is controversial, and the risk of malignant upgrade varies between studies. This study aimed to evaluate the factors affecting the risk of upgrading to breast cancer in patients diagnosed with B3 lesions by core biopsy.</p><p><strong>Methods: </strong>A total of 410 patients diagnosed with B3 lesions by core biopsy and subsequently undergoing surgical excision were evaluated. Patients who did not undergo surgical excision or were not followed up at our center were excluded. Patients were analyzed based on demographic, clinical, radiological, and pathological findings.</p><p><strong>Results: </strong>All 410 patients included in the study were women, with a median age of 47 years (range 21-78). An upgrade to in situ or invasive disease was observed in 117 of the 410 patients (28.5%). In univariate analysis, age, mammographic findings, histopathological type, and atypia in core biopsy were identified as significant factors affecting the upgrade rate (<i>p</i> = 0.046, <i>p</i> = 0.028, <i>p</i> < 0.001, and <i>p</i> < 0.001, respectively). In multivariate analysis, the presence of atypia (<i>p</i> < 0.001) and a diagnosis of atypical ductal hyperplasia (ADH) (<i>p</i> = 0.026) were determined to be independent variables that increase the upgrade rate.</p><p><strong>Conclusion: </strong>Surgical excision or vacuum-assisted excision may be more appropriate for ADH and B3 lesions with atypia on core biopsy.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"1-7"},"PeriodicalIF":2.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}